^
    Back
    Association details:
    Biomarker:EGFR G719A
    Cancer:Non Small Cell Lung Cancer
    Drug:Vizimpro (dacomitinib) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

    Excerpt:
    ...18G719A+20S768I, 18 E709X+21L861Q) are also eligible....
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

    Published date:
    04/22/2021
    Excerpt:
    One patient with an original sensitizing EGFR G719A mutation and one patient without molecular testing available had partial responses...The patient with EGFR G719A has an ongoing response at 17 months...we found that dacomitinib after disease progression on osimertinib has limited benefit.
    DOI:
    10.1200/PO.21.00005